厄洛替尼减轻残余肾大鼠慢性肾脏病进展
该研究在5/6肾切除Sprague Dawley大鼠中给予厄洛替尼或溶媒8周,发现厄洛替尼可降低血肌酐、蛋白尿及纤维化基因表达,减轻肾小球硬化和肾小管间质损伤评分,并减少炎症。体外实验显示厄洛替尼抑制HB-EGF诱导的Akt和ERK1/2活化。提示阻断EGFR可能成为CKD治疗新策略。
要点
- 厄洛替尼可延缓5/6肾切除大鼠CKD进展,减少蛋白尿和血肌酐。
- 厄洛替尼减轻肾小球硬化、肾小管间质损伤及炎症细胞浸润。
- 体外厄洛替尼抑制HB-EGF诱导的Akt和ERK1/2信号通路活化。
核心结论
- 厄洛替尼通过抑制Akt和ERK1/2信号通路及抗炎作用,减轻5/6肾切除大鼠的肾纤维化和CKD进展。
研究设计与样本
- Sprague Dawley大鼠行5/6肾切除,术后2周起给予厄洛替尼或溶媒,持续8周。
- 体外使用正常人系膜细胞和近端小管细胞,用western blotting检测厄洛替尼对纤维化相关信号通路的抑制作用。
主要发现
- 厄洛替尼治疗降低血肌酐、蛋白尿、肾皮质促纤维化基因水平及肾小球硬化和肾小管间质损伤评分。
- 厄洛替尼减轻肾小管间质巨噬细胞浸润及多种促炎细胞因子基因表达。
- 厄洛替尼预处理抑制HB-EGF诱导的正常人系膜细胞和近端小管细胞中Akt和ERK1/2活化。
临床怎么用
- 厄洛替尼作为EGFR酪氨酸激酶抑制剂,可能为CKD抗纤维化治疗提供新方向,但尚需临床研究验证。
局限性
- 研究仅在大鼠模型和体外细胞中开展,尚未在人体中验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasing evidence indicates that epidermal growth factor receptor (EGFR) has a pathogenic role in renal fibrosis. Currently no effective treatment can completely halt the progression of chronic kidney disease (CKD). This study was undertaken to investigate the renoprotective effects of erlotinib, a tyrosine kinase inhibitor that can block EGFR activity in the progression of CKD and the mechanisms involved. METHODS: Sprague Dawley rats with 5/6 nephrectomy were administered either erlotinib or vehicle from 2 weeks after surgery and for a period of 8 weeks. Blood pressure, proteinuria and serum creatinine were measured periodically. Renal morphological investigations were performed at sacrifice. In vitro, we used normal human mesangial cells (NHMCs) and human proximal tubular cells to investigate the inhibitory effects of erlotinib on renal fibrosis-associated signaling pathways by western blotting. RESULTS: Erlotinib treatment significantly blunted the progression of CKD as evidenced by reduced levels of serum creatinine, proteinuria and renal cortical profibrogenic genes and scores of glomerulosclerosis and tubulointerstitial damage. Tubulointerstitial macrophage infiltration and multiple pro-inflammatory cytokine gene expression levels were also attenuated by erlotinib treatment. In vitro, heparin-binding epidermal growth factor-like growth factor-induced Akt and extracellular-regulated kinase (ERK) 1/2 activation in normal human mesangial cells and human proximal tubular cells was inhibited by pretreatment with erlotinib. CONCLUSIONS: EGFR blocking by erlotinib protected against renal fibrosis in 5/6 nephrectomized rats via inhibition of Akt and ERK 1/2 signaling pathways, which are associated with renal fibrosis. Erlotinib also has anti-inflammatory properties, which may contribute to its renoprotective effects. Erlotinib represents a potential novel therapeutic strategy for the treatment of CKD.
引用
- Yamamoto Y, Iyoda M, Tachibana S, et al. Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney. Nephrol Dial Transplant. 2018. PMID: 28992288. doi:10.1093/ndt/gfx264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。